Lead Product(s) : Atovaquone,Inapplicable
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Fresenius Kabi AG
Deal Size : Inapplicable
Deal Type : Inapplicable
Quotient Doses Volunteers in Malaria Venture’s Long-Acting Injectable Prevention Study
Details : MMV371 is a prodrug of atovaquone (selective inhibitor of cytochrome bc1 complex), ben investigated for malaria in adults.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 28, 2024
Lead Product(s) : Atovaquone,Inapplicable
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Fresenius Kabi AG
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : MK-7602,Artemether,Lumefantrine,Primaquine Diphosphate,Artesunate,Atovaquone,Proguanil
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study to Evaluate Antimalarial Activity and Safety of MK-7602 in Healthy Adults (MK-7602-003)
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
March 06, 2024
Lead Product(s) : MK-7602,Artemether,Lumefantrine,Primaquine Diphosphate,Artesunate,Atovaquone,Proguanil
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Atovaquone,Inapplicable
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Richmond Pharmacology
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 30, 2021
Lead Product(s) : Atovaquone,Inapplicable
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Richmond Pharmacology
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Atovaquone,Azithromycin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
TGen and HonorHealth trial atovaquone plus azithromycin for Covid-19
Details : Atovaquone plus azithromycin combination was studied in other infectious disease and is expected to offer a well-tolerated option for patients infected with the novel coronavirus.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 05, 2020
Lead Product(s) : Atovaquone,Azithromycin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Atovaquone,Proguanil
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Richmond Pharmacology
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 28, 2019
Lead Product(s) : Atovaquone,Proguanil
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Richmond Pharmacology
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Atovaquone,Proguanil,P. Falciparum Sporozoites
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Sanaria
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 08, 2016
Lead Product(s) : Atovaquone,Proguanil,P. Falciparum Sporozoites
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Sanaria
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Atovaquone,Proguanil
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 21, 2013
Lead Product(s) : Atovaquone,Proguanil
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sevuparin Sodium,Atovaquone,Proguanil
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I/ Phase II
Sponsor : University of Oxford
Deal Size : Inapplicable
Deal Type : Inapplicable
Sevuparin/DF02 as an Adjunctive Therapy in Subjects Affected With Uncomplicated Falciparum Malaria
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 28, 2011
Lead Product(s) : Sevuparin Sodium,Atovaquone,Proguanil
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I/ Phase II
Sponsor : University of Oxford
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Mefloquine,Immunization,Atovaquone,Proguanil
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Sponsor : ZonMw
Deal Size : Inapplicable
Deal Type : Inapplicable
Immunization With Plasmodium Falciparum Sporozoites Under Chloroquine Versus Mefloquine Prophylaxis
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 25, 2011
Lead Product(s) : Mefloquine,Immunization,Atovaquone,Proguanil
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Sponsor : ZonMw
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
Quotient Sciences- Molecule to Cure. Fast.
